0000899243-20-012750.txt : 20200511
0000899243-20-012750.hdr.sgml : 20200511
20200511214628
ACCESSION NUMBER: 0000899243-20-012750
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200508
FILED AS OF DATE: 20200511
DATE AS OF CHANGE: 20200511
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FREYMAN THOMAS C
CENTRAL INDEX KEY: 0001239126
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36867
FILM NUMBER: 20866898
MAIL ADDRESS:
STREET 1: 500 NORTH FIELD DRIVE
CITY: LAKE FOREST
STATE: IL
ZIP: 60045
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allergan plc
CENTRAL INDEX KEY: 0001578845
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK
CITY: COOLOCK, DUBLIN
STATE: L2
ZIP: D17 E400
BUSINESS PHONE: (216) 523-5000
MAIL ADDRESS:
STREET 1: CLONSHAUGH BUSINESS AND TECHNOLOGY PARK
CITY: COOLOCK, DUBLIN
STATE: L2
ZIP: D17 E400
FORMER COMPANY:
FORMER CONFORMED NAME: Actavis plc
DATE OF NAME CHANGE: 20130930
FORMER COMPANY:
FORMER CONFORMED NAME: Actavis Ltd
DATE OF NAME CHANGE: 20130607
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-08
1
0001578845
Allergan plc
AGN
0001239126
FREYMAN THOMAS C
CLONSHAUGH BUSINESS AND
TECHNOLOGY PARK, COOLOCK, CO.
DUBLIN
L2
D17 E400
IRELAND
1
0
0
0
Ordinary Shares, par value $0.0001
2020-05-08
4
D
0
2983
0.00
D
0
D
Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
/s/ Kira M. Schwartz, Attorney-in-Fact for the Reporting Person
2020-05-08